Ryvu Therapeutics SA Statistics
Ryvu Therapeutics SA (9Y4) Stock Statistics & Valuation Metrics
Total Valuation
Ryvu Therapeutics SA has a market cap or net worth of EUR 90.29M. The enterprise value is EUR 318.33M.
- Market Cap
- EUR 90.29M
- Enterprise Value
- EUR 318.33M
Share Statistics
Ryvu Therapeutics SA has 23,120,148 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 23,120,148
- Owned by Insiders
- ―
- Owned by Institutions
- 0.02%
Financial Efficiency
Ryvu Therapeutics SA’s return on equity (ROE) is -1.88 and return on invested capital (ROIC) is -74.78%.
- Return on Equity (ROE)
- -1.88
- Return on Assets (ROA)
- -0.45
- Return on Invested Capital (ROIC)
- -74.78%
- Return on Capital Employed (ROCE)
- -0.75
- Revenue Per Employee
- 273.04K
- Profits Per Employee
- -443.99K
- Employee Count
- 228
- Asset Turnover
- 0.28
- Inventory Turnover
- 134.30
Valuation Ratios
The current PE Ratio of Ryvu Therapeutics SA is -5.89. Ryvu Therapeutics SA’s PEG ratio is -0.10.
- PE Ratio
- -5.89
- PS Ratio
- 6.62
- PB Ratio
- 13.59
- Price to FCF
- -4.89
- Price to Operating Cash Flow
- -5.04
- PEG Ratio
- -0.10
Income Statement
In the last 12 months, Ryvu Therapeutics SA had revenue of 62.25M and earned -101.23M in profits. Earnings per share was -4.38.
- Revenue
- 62.25M
- Gross Profit
- -117.03M
- Operating Income
- -122.15M
- Pretax Income
- -101.14M
- Net Income
- -101.23M
- EBITDA
- -112.71M
- Earnings Per Share (EPS)
- -4.38
Cash Flow
In the last 12 months, operating cash flow was -76.54M and capital expenditures -7.21M, giving a free cash flow of -83.75M billion.
- Operating Cash Flow
- -76.54M
- Free Cash Flow
- -83.75M
- Free Cash Flow per Share
- -3.85
Dividends & Yields
Ryvu Therapeutics SA pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -20.12%
- Earnings Yield
- -17.36%
Stock Price Statistics
- Beta
- 0.51
- 52-Week Price Change
- -33.05%
- 50-Day Moving Average
- 3.68
- 200-Day Moving Average
- 4.33
- Relative Strength Index (RSI)
- 41.44
- Average Volume (3m)
- 977
Important Dates
Ryvu Therapeutics SA upcoming earnings date is Mar 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 16, 2027
- Ex-Dividend Date
- ―
Financial Position
Ryvu Therapeutics SA as a current ratio of 2.26, with Debt / Equity ratio of 133.22%
- Current Ratio
- 2.26
- Quick Ratio
- 2.24
- Debt to Market Cap
- 0.11
- Net Debt to EBITDA
- -0.11
- Interest Coverage Ratio
- -13.88
Taxes
In the past 12 months, Ryvu Therapeutics SA has paid 88.00K in taxes.
- Income Tax
- 88.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Ryvu Therapeutics SA EV to EBITDA ratio is -6.63, with an EV/FCF ratio of -5.26.
- EV to Sales
- 7.12
- EV to EBITDA
- -6.63
- EV to Free Cash Flow
- -5.26
- EV to Operating Cash Flow
- -5.75
Balance Sheet
Ryvu Therapeutics SA has EUR 74.74M in cash and marketable securities with EUR 74.94M in debt, giving a net cash position of -EUR 198.00K billion.
- Cash & Marketable Securities
- EUR 74.74M
- Total Debt
- EUR 74.94M
- Net Cash
- -EUR 198.00K
- Net Cash Per Share
- -EUR 0.01
- Tangible Book Value Per Share
- EUR 1.02
Margins
Gross margin is -48.97%, with operating margin of -134.74%, and net profit margin of -109.93%.
- Gross Margin
- -48.97%
- Operating Margin
- -134.74%
- Pretax Margin
- -109.27%
- Net Profit Margin
- -109.93%
- EBITDA Margin
- -107.36%
- EBIT Margin
- -121.70%
Analyst Forecast
The average price target for Ryvu Therapeutics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -11.09%
- EPS Growth Forecast
- 43.34%
